Müller R E, Traish A M, Wotiz H H
Endocrinology. 1985 Nov;117(5):1839-47. doi: 10.1210/endo-117-5-1839.
The partial agonist and antagonist properties of estriol (E3) have been related to the brief nuclear retention of receptor-E3 complexes and to the lower affinity of E3 for the receptor compared to estradiol (E2). More recently, it was proposed that the partial agonist/antagonist activity of E3 may be due to its ability to eliminate positive cooperative binding of [3H]E2 to cytosolic estrogen receptor. In this model, positive cooperativity is related to receptor activation and transformation. We first examined the long term effects of E3 on E2 action in vivo. Mature ovariectomized rats were treated for 16 days with E2, E3, or mixtures of these two substances delivered through Alzet pumps at a constant hourly rate (E2, 0.04 microgram; E3, 0.4 and 0.04 microgram; E2 and E3, 0.04 and 0.4 microgram). The effects of E3 on uterine growth, induction of progesterone receptor synthesis, and activation (nuclear binding) of estrogen receptor suggest that when given continuously, E3 acts as a full agonist and does not inhibit E2 action. Furthermore, incubation of uteri at 37 C with [3H]E2 in the presence of a 1- to 20-fold molar excess of nonradioactive E3 did not alter the subcellular distribution of receptor-[3H]E2 complexes (80% nuclear and 20% cytosolic), demonstrating that E3 does not inhibit E2-induced receptor activation (i.e. the increased nuclear binding of receptor). Similarly, 4S to 5S transformation of [3H]E2-labeled estrogen receptor in intact uteri was not inhibited by E3. Equilibrium binding of [3H]E2 to uterine cell suspensions at physiological temperature (37 C) was noncooperative; nonradioactive E3 did not alter the affinity of the estrogen receptor for [3H]E2; Dixon plot analysis indicates that E3 is a purely competitive inhibitor of [3H]E2 binding. This, in conjunction with the lower affinity of the receptor for E3 than for E2, adequately explains the agonistic-antagonistic properties of E3.(ABSTRACT TRUNCATED AT 250 WORDS)
雌三醇(E3)的部分激动剂和拮抗剂特性与受体 - E3复合物在细胞核内的短暂滞留以及与雌二醇(E2)相比E3对受体的较低亲和力有关。最近有人提出,E3的部分激动剂/拮抗剂活性可能是由于其能够消除[3H]E2与胞质雌激素受体的正协同结合。在这个模型中,正协同性与受体激活和转化有关。我们首先研究了E3对体内E2作用的长期影响。成熟的去卵巢大鼠通过Alzet泵以恒定的每小时速率接受E2、E3或这两种物质的混合物治疗16天(E2,0.04微克;E3,0.4和0.04微克;E2和E3,0.04和0.4微克)。E3对子宫生长、孕激素受体合成的诱导以及雌激素受体激活(核结合)的影响表明,持续给予时,E3起完全激动剂的作用,并不抑制E2的作用。此外,在1至20倍摩尔过量的非放射性E3存在下,子宫在37℃与[3H]E2孵育并未改变受体 - [3H]E2复合物的亚细胞分布(80%在细胞核内,20%在胞质内),表明E3不抑制E2诱导的受体激活(即受体核结合增加)。同样,完整子宫中[3H]E2标记的雌激素受体的4S到5S转化也未被E3抑制。在生理温度(37℃)下,[3H]E2与子宫细胞悬液的平衡结合是非协同的;非放射性E3并未改变雌激素受体对[3H]E2的亲和力;Dixon图分析表明E3是[3H]E2结合的纯竞争性抑制剂。这与受体对E3的亲和力低于对E2的亲和力相结合,充分解释了E3的激动 - 拮抗特性。(摘要截短于250字)